Nash data are due for Terns and Inventiva, as Marinus aims to expand its rare disease offering.
J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.
Ultragenyx and Mereo celebrate a mid-stage biomarker win, but have much to do in phase 3.
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Vatiquinone’s pivotal failure in Friedreich’s ataxia prompts a data dredge to come up with a regulatory package. And why not?
Asian developers dominate biopharma’s gout pipeline, with Selecta and Sobi’s SEL-212 standing out as a rare globally focused project.